Pacific Biosciences Names Michael W. Hunkapiller Chief Executive Officer
Friday, January 6, 2012
Single Molecule Real Time (SMRT®) sequencing products, today
announced the appointment of
and Chief Executive Officer effective immediately. He succeeds
Martin, who will remain on the Board of Directors through the company’s
next annual meeting of shareholders.
Dr. Hunkapiller was named Executive Chairman of PacBio’s Board of
helping build Applied Biosystems (“ABI,” now part of
Inc.) into a market leader in the life sciences industry. From 1995 to
2004 he served as ABI’s President and
in PacBio and joined the company’s Board of Directors. Dr. Hunkapiller
will continue to represent
“I am excited and honored to take on the role of President and CEO of
PacBio,” said Dr. Hunkapiller. “Since joining the company’s Board, I
have always believed that our SMRT technology would play a significant
role in biological research and the advancement of medical therapies.
Now that we have begun to deliver products to customers, I am more
convinced than ever that we are on our way to fulfilling that promise.
The company is in great position with the people, products, and cash to
drive the adoption of its disruptive technology.”
efforts in transforming PacBio from an early stage R&D company to a
leader in single molecule technology. Mike brings unmatched expertise,
experience and relationships with customers in the life science tools
market and is uniquely qualified to lead the company through its next
stage of growth.”
molecule sequencing was a tremendous achievement for PacBio, and Mike is
now the ideal person to drive the broader adoption of PacBio’s products.
I am in support of this decision and am looking forward to identifying
my next exciting career venture.”
For more information about Pacific Biosciences, please visit www.pacificbiosciences.com.
You can also follow the company on Twitter www.twitter.com/pacbio.
About Pacific Biosciences
Pacific Biosciences’ mission is to transform the way humankind acquires,
processes and interprets data from living systems through the design,
development and commercialization of innovative tools for biological
research. The company has developed a novel approach to studying the
synthesis and regulation of DNA, RNA and proteins. Combining recent
advances in nanofabrication, biochemistry, molecular biology, surface
chemistry and optics, Pacific Biosciences has created a powerful
technology platform called single molecule, real-time, or SMRT®,
technology. SMRT technology enables real-time analysis of biomolecules
with single molecule resolution, which has the potential to transform
the understanding of biological systems by providing a window into these
systems that has not previously been open for scientific study.
This press release contains forward-looking statements. Forward-looking
statements may contain words such as “believe,” “may,” “estimate,”
“anticipate,” “continue,” “intend,” “expect,” “plan,” the negative of
these terms, or other similar expressions, and include the assumptions
that underlie such statements. Such statements include, but are not
limited to, statements regarding the Company’s SMRT technology and the
Company’s growth. These statements are subject to known and unknown
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements, including
but not limited to risks discussed from time to time in documents
and Exchange Commission, including the risks identified under the
section captioned “Risk Factors” in its recently filed Quarterly Report
on Form 10-Q. All forward-looking statements are based on estimates,
projections and assumptions as of the date hereof. Pacific Biosciences
undertakes no obligation to update any forward-looking statements.
For Pacific Biosciences
News Provided by Acquire Media